Peptide Sprays vs Injections: How Delivery Method Affects Research Use

Peptide delivery methods, also called routes of administration, are the ways a peptide reaches its target in a study or a treatment. Peptide sprays and injections sit at opposite ends of the range. An injection places the peptide in tissue or the bloodstream, while a nasal spray depends on absorption through the lining of the nose. 

The spray evidence in this guide concerns the nasal route; sprays supplied for other routes, such as oral or sublingual use, are not covered. Injectable peptides account for about 78% of approved administration routes for peptide products. Approved medicines regulated by the FDA and the MHRA come with published labels, which supply reliable figures for each route. River Peptides supplies compounds for in vitro research only, and nothing here is guidance for use in people. 

Peptide Delivery Methods: Why the Route Changes Research Results 

Bioavailability is the share of a dose that reaches the bloodstream, and the route strongly influences it. Impacts and efficacy of  Peptides are especially sensitive to how they have been administered. 

Ibeanu and colleagues describe polypeptides as often having poor pharmacokinetics and limited permeability across biological barriers, so frequent administration is generally needed to maintain adequate levels. 

How Peptide Type and Formulation Affect the Route

Semaglutide shows the effect within one molecule. A peptide of about 4,100 daltons, it has an absolute bioavailability of 89% after subcutaneous injection. As a tablet, the label’s estimates run from 0.4% to 2% across the tablet strengths. The tablet is co-formulated with an absorption enhancer, salcaprozate sodium (SNAC), which the label says facilitates absorption. Chemical modifications to the peptide itself protect it from the DPP-4 enzyme and prolong its half-life through albumin binding. 

How the research Objective affects the route

Exposure in a study depends on the peptide, the route, the formulation and the experimental model together. Duration is one variable. Many polypeptides clear quickly, and strategies such as albumin binding, PEGylation and depot formulations aim to prolong their action. 

Semaglutide’s elimination half-life is about one week, which the label attributes mainly to albumin binding. A result for one combination of peptide, route and formulation therefore does not carry over automatically to another. 

How Do Injectable Peptides Work?

Injectable peptides are peptide products formulated for injection under the skin, into muscle or into a vein.

How Do Peptides Work in the Body?

Peptides are short chains of amino acids, and many approved peptide medicines are analogues of natural hormones that act by binding to receptors. Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1 that selectively binds to and activates the GLP-1 receptor. Desmopressin is a synthetic analogue of vasopressin: two chemical changes largely remove its vasopressor action while enhancing and prolonging its antidiuretic action.

Why Injection Is the Established Route 

Peptides are generally inactive when swallowed, and few oral peptide products are approved. A 2020 analysis of peptide products approved in the US, Europe and Japan found that injectables are the most common dosage forms, mainly subcutaneous, intravenous and intramuscular. It also noted the poor absorption of oral products. Parenteral here means any route that bypasses the gut, usually injection. 

Delivery Advantages and Limits of Injection

Injection avoids the gut entirely. An intravenous dose is assumed to be 100% available, which makes it the reference for other routes. Subcutaneous bioavailability typically trails the intravenous route, with reports of 30% to 100% in humans across medicines, and semaglutide sits near the top of that range at 89%.

The limits are practical. Intravenous injection is invasive and needs venous access. Peptides often have very short half-lives after injection, so frequent administration is generally needed unless the formulation extends their action.

How Do Peptide Sprays Work?

How a Nasal Spray Delivers a Peptide 

A nasal spray places a metered volume of solution on the nasal lining, and the peptide must cross that lining to reach the bloodstream. Only a small volume can be sprayed, so a peptide needs enough solubility to carry a useful amount in it. A retrospective analysis found that peptides of up to about 6,000 daltons have been delivered intranasally. Permeation enhancers (which help peptides cross the lining) and mucoadhesives (which hold a formulation against it) show promise in improving bioavailability. 

A Worked Example: Desmopressin Nasal Spray 

Desmopressin nasal spray is the established nasal example. Its UK summary of product characteristics states that systemic bioavailability is approximately 10% of the dose administered, with peak plasma concentration after about 50 minutes. 

What the Evidence Covers, and What It Does Not 

Intranasal delivery is one of eleven routes approved for peptide products, and nasal desmopressin is a long-standing example. Its label notes that absorption may be irregular where the nasal lining is swollen or scarred. No human data on peptide spray bioavailability for research compounds was located in peer-reviewed sources. Findings from a formulated approved spray do not transfer automatically to other peptides or solutions. A metered spray delivers a fixed volume, but delivered volume and absorbed amount are different quantities, as the 10% figure above shows. 

Peptide Sprays vs Injections Compared 

Approved Medicines as Worked Examples

These are prescription medicines, shown only to illustrate route and formulation. Semaglutide is supplied as an injection (in single-patient-use pens or single-dose prefilled syringes) and as a tablet, which allows one peptide to be compared across routes. Desmopressin nasal spray holds a UK marketing authorisation, as its summary of product characteristics records.

Injectable Peptides Side Effects: What Approved Medicines’ Labels Report

What the Labels Cover and What They Do Not

Labels list the reactions seen in trials and reported after approval for one product, in the people it was studied in. Research compounds have no equivalent dataset, so no safety profile is established for them, and the absence of a published list is not evidence of safety.

Adverse Reactions Listed for an Approved Injectable

The FDA label for semaglutide injection reports the following for the people studied for its approved uses:

• Most common adverse reactions: nausea, vomiting, diarrhoea, abdominal pain and constipation. In placebo-controlled trials, gastrointestinal reactions occurred in 15.3% of placebo recipients and in 32.7% to 36.4% of those given semaglutide.
• Boxed warning: in rodents, semaglutide causes thyroid C-cell tumours, and the human relevance has not been determined.
• Further warnings: pancreatitis, gallbladder disease, kidney injury linked to dehydration, severe allergic reactions, and low blood sugar when combined with insulin or sulfonylurea medicines.

Injection-Related Reactions and the Risks of Unregulated Products

Among the peptide injection side effects documented on labels, injection-site reactions such as discomfort and redness were reported in 0.2% of people given semaglutide in placebo-controlled trials. The same label warns that pens must never be shared between patients, because pen-sharing risks transmitting blood-borne pathogens. Products sold online as research-use-only are not regulated in the same way as licensed medicines, according to the chief scientist of the Royal Pharmaceutical Society, as reported in The Pharmacist.

Side Effects Listed for an Approved Nasal Spray

The UK summary of product characteristics for desmopressin nasal spray groups its listed reactions by frequency:

• Common: conjunctivitis and asthenia.
• Uncommon: nasal congestion, nosebleeds, rhinitis, headache, nausea, abdominal cramps and vomiting.
• Rare: low blood sodium (hyponatraemia).

The document also notes post-marketing evidence of severe hyponatraemia with the nasal spray formulation.

Reporting Side Effects

Patients, carers and healthcare professionals in the UK can report suspected side effects from a medicine to the MHRA through the Yellow Card scheme, as set out in the MHRA’s guidance.

Other ways Peptides are administered 

Oral Peptides

Oral bioavailability for peptides and proteins is below 1%, and below 0.1% in some cases, with cyclosporine a noted exception. Semaglutide tablets reach an estimated 0.4% to 2% even with an absorption enhancer in the formulation.

Pulmonary and Transdermal Routes

Inhaled human insulin is FDA-approved as a dry powder for oral inhalation, and its label lists acute bronchospasm among its warnings. Through the skin, a drug generally needs a molecular weight below about 1,000 daltons, and most protein and peptide drugs are hydrophilic and macromolecular. Microneedles, arrays of needles under 1 mm, bypass the barrier through reversible microchannels.

Peptide Sprays and Injections at River Peptides

River Peptides’ range includes pre-mixed sprays, which are ready-to-use solutions, and lyophilised powders. All forms of our peptides are sent for independent testing in third-party laboratories, including Janoshik Laboratories in the Czech Republic and Analiza Bialek in Poland. As a business we hold a ISO 9001 quality management and ISO 14001 environmental management certification. 

Browse our fall range of third-party tested peptides.

Peptide Sprays vs Injections FAQs

Do peptide sprays deliver as much peptide as injections?

Not in the worked examples. Semaglutide injection has an absolute bioavailability of 89%, against about 10% for desmopressin nasal spray. These are different peptides, so the figures show the range regulators have documented and do not compare the routes head to head.

What are the side effects of injectable peptides?

Labels for approved injectable peptide medicines list reactions such as nausea, vomiting, diarrhoea, abdominal pain, constipation and injection-site reactions, together with several warnings. Research compounds have no equivalent dataset, so no safety profile is established for them. The side effects section above sets out the label details.

What are the differences between a peptide spray and an injection?

The differences between peptide sprays and subcutaneous injections come down to how the peptide works in the body and how much active drug effectively reaches your target tissue. Injectable peptides such as BPC-157 are best for systemic repair, whilst nasal spray peptides such as semax are best for brain and central nervous system targets.

Is it better to inject or oral peptides?

As injectable peptides achieve close to 75% to 90% bioavailability, they are often the more effective and oral peptide delivery method in comparison to an oral peptide which often has less than 10% bioavailability.